Bioarray Genetics next generation predictive tests leverage the potential of the genomic revolution to deliver clinically actionable information that optimizes treatment planning at the beginning of the cancer patient's journey. By moving away from the 'one size fits all' approach to cancer treatment, both patients and doctors can have increased confidence in treatment decisions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/06/17 | $4,000,000 | Series B |
Connecticut Innovations GF Securities Quark Venture | undisclosed |
